The effect of benralizumab on inflammation in severe asthma: a real-life analysis
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on a...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
SAGE Publishing
2024-12-01
|
| Ráidu: | Therapeutic Advances in Respiratory Disease |
| Liŋkkat: | https://doi.org/10.1177/17534666241304685 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|